Alcon Acquired by Novartis
On December 15, 2010, Novartis (NYSE: NVS) agreed to acquire the remaining shares of Alcon, Inc. (NYSE: ACL) it doesn't currently own for $168 per share.
The merger consideration will be comprised of a combination of Novartis shares and, if necessary, a cash contingent value amount to result in a total value of $168 per share.
Upon completion of the merger, Alcon will become the second largest division within Novartis. CIBA VISION and select Novartis ophthalmic medicines will be integrated into Alcon, forming an organization with more than $8.7 billion in sales covering over 70 percent of the eye care segment.
The merger consideration will be comprised of a combination of Novartis shares and, if necessary, a cash contingent value amount to result in a total value of $168 per share.
Upon completion of the merger, Alcon will become the second largest division within Novartis. CIBA VISION and select Novartis ophthalmic medicines will be integrated into Alcon, forming an organization with more than $8.7 billion in sales covering over 70 percent of the eye care segment.
View Older Stories
-
Verona Pharma plc (VRNA) Appoints Christina Ackermann to its Board
-
Oculis (OCS) Opens New Offices in the US
-
Mallinckrodt (MNK) Appoints Peter Richardson as Chief Scientific Officer
-
ADC Therapeutics SA (ADCT) Appoints Jose Carmona as CFO
-
Alcon (ALC) Acquires Aerie Pharmaceuticals (AERI) for $15.25/sh or $770M
-
Immunocore (IMCR) Appoints Siddharth (Sid) Kaul to its Board
-
Opthea (OPT) Appoints Quinton Oswald and Susan Orr to its Board
-
Graybug Vision Inc. (GRAY) Appoints Dirk Sauer to its Board
-
Inari Medical, Inc. (NARI) Appoints Robert Warner to its Board
-
Chicos FAS (CHS) Names Nike's Eli Kumekpor to Board
-
RBC Capital Sees Positive Read-Through to Bausch Health Companies (BHC) from Alcon's (ALC) EPS
-
Opthea (OPT) Appoints Judith Robertson as CCO to Lead Commercialization of OPT-302 for Wet AMD
-
Alcon (ALC) to Acquire Ivantis for $475M Upfront
-
Ault Global Holdings (DPW) to Acquire up to 40% of Adtech Pharma, Inc.
-
Opthea (OPT) Named Dr. Julia Haller and Ms. Judith Robertson to Board
-
Alcon (ALC) to Acquire U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza
-
Alcon Inc. (ALC) Capital Markets Day Is Likely a Positive Catalyst - Jefferies
-
UPDATE: BTIG Upgrades Alcon Inc. (ALC) to Buy
-
CDK Global (CDK) Announces Eric Guerin as CFO
-
Graybug Vision Inc. (GRAY) Adds Christina Ackermann, Eric Bjerkholt and Julie Eastland to Board
-
Alcon (ALC) Announces FDA Approval of the OTC Switch of Pataday Once Daily Relief Extra Strength
-
Aldeyra Therapeutics (ALDX) Announces Strategic Prioritization of Late-Stage Clinical Pipeline in Ocular Disease
-
Edward Jones Reiterates Buy Rating on Novartis (NVS), Favors Attractive Pipeline
-
Precision BioSciences (DTIL) Announces Kevin J. Buehler to Board
-
Novartis (NVS) Tops Q2 EPS by 12c, Offers Outlook
-
Berenberg Starts Alcon Inc. (ALC) at Hold
-
Bausch Health Companies (BHC) $41 PT Reiterated At Mizuho After A Post Novartis Spin SOTP Analysis
-
Novartis (NVS) calls active on Alcon (ALC) eye care spin-off
-
Alcon (ALC) to Debut on NYSE Following Novartis Spin-Off
-
Cleveland Research Starts Alcon Inc. (ALC) at Neutral
-
Pre-Open Movers 08/29: (GKOS) (TLRY) (SPHS) (EXPR) Higher; (AEO) (DKS) (ROKU) Lower
-
Glaukos Corporation (GKOS) Gains After Alcon (NVS) Announces Withdrawal of CyPass Micro-Stent from Market
-
Alcon announces voluntary global market withdrawal of CyPass Micro-Stent for surgical glaucoma
-
Aerie Pharmaceuticals Announces Appointment of Jeffrey White, Ph.D. as Director, Toxicology and Pharmacokinetics
-
MerLion Regains North American Rights to XTOROTM FDA-Approved Antibiotic for Treatment of Ear Infections
-
Alcon introduces NGENUITY® 3D Visualization System with DATAFUSION™ to simplify, customize vitreoretinal surgery
-
Novartis (NVS) Tops Q2 EPS by 2c (Earlier)
-
Novartis hints at 2018 outlook hike despite drug price freeze
-
Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company
-
Sinovant Sciences, Company Focused on the Development of Innovative Medicines in China, Unveiled at Event in Beijing
-
Novartis chairman says Alcon worth $20 billion-$30 billion: Finanz und Wirtschaft
-
Novartis (NVS) to Spinoff Alcon (Earlier)
-
Novartis hands investors Alcon spin-off, $5 billion share buyback
-
Novartis announces intention to seek shareholder approval for 100% spinoff of Alcon eye care devices business; initiates share buyback of up to USD 5 bn
-
uStudio Introduces First Secure Podcast Solution for Private Enterprise Communications
-
Novartis International AG: Alcon AcrySof® IQ PanOptix® trifocal intraocular lens shows superior visual performance in head-to-head trial post-cataract surgery
-
Earth Science Laboratories Expands Research and Development
-
Alcon teams up with Venus Williams, tennis champion and dry eye sufferer, to launch Systane® Complete eye drops
-
Novartis top lawyer exits over Trump attorney deal 'mistake'
-
At the Meet Novartis Management investor event, Novartis highlights strategy to focus the company and drive sustainable growth